ENTITY
WuXi XDC

WuXi XDC (2268 HK)

179
Analysis
Industrials • China
WuXi XDC is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and other bioconjugates. The company offers integrated, end-to-end services for the discovery, process development, and GMP manufacturing of bioconjugates, monoclonal antibody intermediates, and payload-linkers. WuXi XDC was founded in 2013 and is headquartered in Wuxi, China.
more
•13 Apr 2025 10:05

HK Connect Flows Weekly (Apr 11th): Tencent, Alibaba, Xiaomi, China Mobile, SMIC, HSBC

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent, Alibaba, Xiaomi, China Mobile, SMIC, HSBC.

Logo
798 Views
Share
•07 Apr 2025 08:40

ECM Weekly (7 Apr 2025) - CATL, Maynilad, Chagee, Lotte Logistics, Sigenergy, Duality, Wuxi XDC

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
800 Views
Share
bullish•WuXi AppTec
•06 Apr 2025 09:18

China Healthcare Weekly (Apr.6) - SASAC to Encourage SOE M&A, WuXi AppTec Disposed XDC Shares Again

​China innovative drug industry will see big financial gains through licensing cooperation. The SASAC released new policy to encourage SOE M&A.WuXi...

Logo
722 Views
Share
bullish•WuXi XDC
•01 Apr 2025 19:11

Wuxi XDC Placement - Following Biologics Playbook, past Deals Have Been Mixed

WuXi AppTec (2359 HK) aims to raise around US$250m via selling around 3.5% stake in WuXi XDC Cayman (2268 HK). In this note, we talk about the deal...

Logo
586 Views
Share
bearish•Wuxi Biologics
•27 Mar 2025 08:55

Wuxi Biologics (2269 HK) - The Concerns Behind 2024 Results and the Outlook in 2025

​WuXi Bio's 2024 results was mainly driven by WuXi XDC, without which growth would be negative. As growth slows down, high valuation is...

Logo
645 Views
Share
x